Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention-Reference-Cited by-同舟云学术

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Published:2015-11 Issue:5 Volume:170 Page:845-854
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Chen Wei Ren,Hu Shun Ying,Chen Yun Dai,Zhang Ying,Qian Geng,Wang Jing,Yang Jun Jie,Wang Zhi Feng,Tian Feng,Ning Qing Xiu

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials;Keeley;Lancet,2003

2. Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function;Aronson;Diabetes Care,2007

3. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes;Ceriello;Diabetes Care,2013

4. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury;Timmers;J Am Coll Cardiol,2009

5. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice;Noyan-Ashraf;Diabetes,2009

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life;Cardiac Failure Review;2024-09-11

2. The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes;Current Cardiology Reports;2024-09-05

3. Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease;2024-08-16

4. Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence;Current Pharmaceutical Design;2024-08

5. Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner;Journal of Endocrinology;2024-06-11